Viewing nowCombinationIdalbi Clopidogrel 40/12.5mg (Azilsartan Medoxomil Potassium, Chlorthalidone)
Potassium Azilsartan Medoxomil 42.68mg · Chlorthalidone 12.5mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 202400975 · Approved 2024.04.25
Essential hypertension not controlled with monotherapy; initial treatment of stage 2 hypertension
This medication is used primarily in patients with essential hypertension who do not achieve adequate blood pressure control with monotherapy using Azilsartan Medoxomil. It is also used as an initial therapy for Stage 2 hypertension patients who require combination therapy to reach their target blood pressure. In other words, it effectively works to control blood pressure stably.
1. Adults The recommended initial dose is 40/12.5 milligrams, taken with water, with or without food. The blood pressure-lowering effect is usually apparent within 1-2 weeks. If blood pressure control is needed after 2-4 weeks, the dose may be increased to 40/25 milligrams. Doses exceeding 40/25 milligrams are not beneficial. 1) Patients whose blood pressure is not adequately controlled with monotherapy: It is recommended that the dose of azilsartan medoxomil be adjusted before administering this medicine. Patients whose blood pressure is not adequately controlled with azilsartan medoxomil monotherapy may be considered for a switch to this medicine. The recommended initial dose is 40/12.5 milligrams once daily. 2) When this medicine is used as initial therapy in patients with stage 2 hypertension, the decision should be based on an assessment of potential benefits and risks, including whether the patient is likely to tolerate the initial dose. The recommended initial dose is 40/12.5 milligrams once daily. 2. Elderly patients No dosage adjustment is necessary when administering this medicine to elderly patients. Although no overall differences in safety or efficacy were observed between elderly and younger patients, greater sensitivity in some elderly patients cannot be ruled out. 3. Patients with renal impairment No dosage adjustment is necessary in patients with mild or moderate renal impairment. 4. Patients with hepatic impairment Experience with this medicine is limited; however, based on clinical findings for azilsartan medoxomil, no dosage adjustment is necessary in patients with mild or moderate hepatic impairment. 5. Patients with intravascular volume depletion In patients with salt depletion or who may have volume depletion (e.g., those with vomiting or diarrhea, or receiving high doses of diuretics), correct the volume depletion before initiating this medicine under close medical supervision.
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This drug can cause serious harm to the fetus and newborn, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with impaired liver function or progressive liver disease may easily disrupt their body's fluid and electrolyte balance, so caution is needed as there is a risk of hepatic encephalopathy. Severe renal disease patients can experience azotemia due to the diuretic component of this drug, and there is a risk of drug accumulation in the body, so caution should be exercised in its use. This drug should not be used in patients who are allergic to this drug or its components, in those who are hypersensitive to certain diuretics, in pregnant or nursing women, in patients with anuria, and in patients with severe liver or kidney impairment. Patients with electrolyte imbalance in the blood, gout, Addison's disease, those undergoing lithium therapy, and patients with certain heart diseases should also be cautioned. In patients with very low blood pressure or reduced blood volume, hypotension may occur, so their condition should be carefully checked before administration, and appropriate measures should be taken if hypotension occurs. Since this drug can affect kidney function, patients with weak kidney function should routinely check their renal function and electrolyte levels through blood tests. Due to the diuretic component, hypokalemia, hyponatremia, and hypercalcemia can occur, thus electrolyte status should be frequently examined in the blood. Patients who need blood sugar control may experience changes in blood sugar levels while taking this drug, so adjustments to diabetes medications may be necessary. This medication may cause dizziness or drowsiness while driving or operating machinery, so caution is advised. There may be interactions when taken concomitantly with other drugs, especially with lithium, potassium-sparing diuretics, and non-steroidal anti-inflammatory drugs (NSAIDs), so should be taken under the supervision of a healthcare professional. It is best to avoid this medication during pregnancy or breastfeeding, and especially during breastfeeding, alternative treatments should be considered for the baby's safety. In case of overdose, symptoms such as hypotension, dizziness, and electrolyte imbalance may occur, and immediate medical attention should be sought, followed by appropriate treatment. This drug should be stored in its original packaging, away from light and moisture, and kept out of reach of children, avoiding transfer to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that does not allow light and airflow, at room temperature between 1 to 30 degrees Celsius. It is also important to store it in a place away from high humidity.
Light red, biconvex, round film-coated tablets
28 tablets/PTP [(14 tablets * 2ea)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationPotassium Azilsartan Medoxomil 42.68mg · Chlorthalidone 12.5mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Potassium Azilsartan Medoxomil 42.68mg · Chlorthalidone 12.5mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Potassium Azilsartan Medoxomil 42.68mg · Chlorthalidone 25mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationPotassium Azilsartan Medoxomil 42.68mg · Chlorthalidone 25mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.